| Literature DB >> 23685433 |
Marc Folcher1, Mingqi Xie, Andrea Spinnler, Martin Fussenegger.
Abstract
Synthetic biology has significantly advanced the design of synthetic control devices, gene circuits and networks that can reprogram mammalian cells in a trigger-inducible manner. Prokaryotic helix-turn-helix motifs have become the standard resource to design synthetic mammalian transcription factors that tune chimeric promoters in a small molecule-responsive manner. We have identified a family of Actinomycetes transcriptional repressor proteins showing a tandem TetR-family signature and have used a synthetic biology-inspired approach to reveal the potential control dynamics of these bi-partite regulators. Daisy-chain assembly of well-characterized prokaryotic repressor proteins such as TetR, ScbR, TtgR or VanR and fusion to either the Herpes simplex transactivation domain VP16 or the Krueppel-associated box domain (KRAB) of the human kox-1 gene resulted in synthetic bi- and even tri-partite mammalian transcription factors that could reversibly program their individual chimeric or hybrid promoters for trigger-adjustable transgene expression using tetracycline (TET), γ-butyrolactones, phloretin and vanillic acid. Detailed characterization of the bi-partite ScbR-TetR-VP16 (ST-TA) transcription factor revealed independent control of TET- and γ-butyrolactone-responsive promoters at high and double-pole double-throw (DPDT) relay switch qualities at low intracellular concentrations. Similar to electromagnetically operated mechanical DPDT relay switches that control two electric circuits by a fully isolated low-power signal, TET programs ST-TA to progressively switch from TetR-specific promoter-driven expression of transgene one to ScbR-specific promoter-driven transcription of transgene two while ST-TA flips back to exclusive transgene 1 expression in the absence of the trigger antibiotic. We suggest that natural repressors and activators with tandem TetR-family signatures may also provide independent as well as DPDT-mediated control of two sets of transgenes in bacteria, and that their synthetic transcription-factor analogs may enable the design of compact therapeutic gene circuits for gene and cell-based therapies.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23685433 PMCID: PMC3711444 DOI: 10.1093/nar/gkt405
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Plasmids and oligonucleotides designed and used in this study
| Plasmid | Description | Reference |
|---|---|---|
| pZeoSV2(+) | Constitutive mammalian expression vector encoding the zeocin resistance gene (PhCMV-zeo-pA) | Invitrogen, CA |
| pDA43 | TET-responsive GLuc expression vector (PhCMV*−1-GLuc-pA) | ( |
| pMF111 | TET-responsive SEAP expression vector (PhCMV*−1-SEAP-pA) | ( |
| pMF205 | Constitutive tTS expression vector (PSV40-tTS-pA) | ( |
| pMG10 | Phloretin-responsive SEAP expression vector (PTtgR1-SEAP-pA) | ( |
| pMG11 | Constitutive TtgA1 expression vector (PSV40-TtgA1-pA) | ( |
| pMG250 | Constitutive VanA1 expression vector (PSV40-VanA1-pA) | ( |
| pMG252 | Vanillic acid-responsive SEAP expression vector (P1VanO2-SEAP-pA) | ( |
| pSAM200 | Constitutive tTA expression vector (PSV40-tTA-pA) | ( |
| pWW122 | Constitutive SCA expression vector (PSV40-SCA-pA) | ( |
| pWW124 | SCB1-responsive SEAP expression vector (PSPA-SEAP-pA) | ( |
| pSEAP2-Control | Constitutive SEAP expression vector (PSV40-SEAP-pA) | Clontech, CA |
| pAS1 | Low-level constitutive ST-TA expression vector (PhCMVmin-ST-TA-pA). PhCMVmin was PCR-amplified from pWW124 using oligonucleotides OAS1 (5′-GCAGCTAGCAGGTCGAGCTCGGTACCCGG-3′) and OAS2 (5′-CAGGCGGCCGCGCTGACTCTAGAGGATCCCCG-3′), restricted with | This work |
| pMX1 | Constitutive ST-TA expression vector (PSV40-ST-TA-pA). ScbR was PCR-amplified from pWW122 using oligonucleotides OMF1 (5′-GGTCCCGGATCGAATTGCGGCCGCTAATTC-3′) and OMF2 (5′-TGAATTCTACCCGCGCGGCTGTACGCGGA-3′), restricted with | This work |
| pMX5 | Constitutive TS-TA expression vector (PSV40-TetR-Kozak-ScbR-VP16-pA). TetR was PCR-amplified from pSAM200 using oligonucleotides OMF1 (5′-GGTCCCGGATCGAATTGCGGCCGCTAATTC-3′) and OMF2 (5′-TGAATTCTACCCGCGCGGCTGTACGCGGA-3′), restricted with | This work |
| pMX6 | Constitutive TV-TA expression vector (PSV40-TetR-VanR-VP16-pA). VanR was PCR-amplified from pMG250 using oligonucleotides OPS213 (5′-GGGTAGAATTCATATGGACATGCCGCGCATAAAGC-3′) and OPS545 (5′-TTTTTCGTACGCGCGCGGCTGTACGCGGAGTCGGCGCGAATGCTCCACGCCGCGCCCAGCGGCGC-3′), restricted with | This work |
| pMX8 | ST-TA/TS-TA-specific TET- and SCB1-responsive hybrid promoter-driven SEAP expression vector (PST-TA/TS-TA1-SEAP-pA; PST-TA/TS-TA1, tetO-21bp-OPapRI-PhCMVmin). | This work |
| PSPA was PCR-amplified from pWW124 using oligonucleotides OMX26 (5′-TAGACGTCTTTACCACTCC′CTATCAGTGATAGAGAAAAGTGAAAGTCGGCCATTGACAAACCGACCGT-3′) and OMX24 (5′-CTTGAGCACATAGCCTGGACCGTTTCCGTA-3′), restricted with | ||
| pMX9 | ST-TA/TS-TA-specific TET- and SCB1-responsive hybrid promoter-driven SEAP expression vector (PST-TA/TS-TA2-SEAP-pA; PST-TA/TS-TA2, tetO-21bp-tetO-21bp-OPapRI-PhCMVmin). | This work |
| PSPA was PCR-amplified from pWW124 using oligonucleotides OMX27 (5′-TAGACGTCCTCTATCAGTGATAGAGAAAAGTGAAAGTCGAGCTCTATCAGTGATAGAGAAAAGTGAAAGTCGGCCATTGACAAACCGACC-3′) and OMX24 (5′-CTTGAGCACATAGCCTGGACCGTTTCCGTA-3′), restricted with | ||
| pMX10 | Constitutive TS-TA expression vector (PSV40-TetR-ScbR-VP16-pA). | This work |
| ScbR was PCR-amplified from pMX5 using oligonucleotides OMX10a (5′-AGAATTCGGGGCATGGCCAAGCAGGACCGG-3′) and OMX10b (5′-TTGGCGCGCGGCTGTACGCGGAGTCCTTCC-3′) to remove the Kozak sequence, restricted with | ||
| pMX25 | Constitutive VT-TA expression vector (PSV40-VanR-TetR-VP16-pA). | This work |
| VanR was PCR-amplified from pMG250 using oligonucleotides OMX12 (5′-CCCGGATCGGAATTGCGGCCGCTAATTCATATGGACATGCCGCGCATAAAGCCGGG-3′) and OMX13 (5′-GCCCCGAATTCTACCCGCGCGGCTGTACGCGGAGTCGGCGCGAATGCTCCACGCCG-3′), restricted with | ||
| pMX27 | Constitutive PTS-TA expression vector (PSV40-TtgR-TetR-ScbR-VP16-pA). | This work |
| TtgR-TetR was PCR-amplified from pMX29 using oligonucleotides OMF1 (5′-GGTCCCGGATCGAATTGCGGCCGCTAATTC-3′) and OMX14 (5′-GCCCCAATTGTACCCGCGCGGCTGTACGCGGACCCACTTTCACATTTAAGTTGTT-3′), restricted with | ||
| pMX29 | Constitutive PT-TA expression vector (PSV40-TtgR-TetR-pA). | This work |
| TtgR was PCR-amplified from pMG11 using oligonucleotides OMF1 (5′-GGTCCCGGATCGAATTGCGGCCGCTAATTC-3′) and OMF2 (5′-TGAATTCTACCCGCGCGGCTGTACGCGGA-3′), restricted with | ||
| pMX31 | Constitutive SP-TA expression vector (PSV40-ScbR-TtgR-pA); | This work |
| TtgR was PCR-amplified from pMG11 using oligonucleotides OMX28 (5′-GGGTAGAATTCATATGGTCCGTCGAACCAAAGAAGA-3′) and OMX29 (5′-TTTTTCGTACGCGCGCGGCTGTACGCGGATTTGCGCAGAGCCGGGCTCAAGCG-3′), restricted with | ||
| pMX63 | Constitutive ST-TS expression vector (PSV40-ScbR-TetR-KRAB-pA). | This work |
| KRAB was excised from pMF205 using | ||
| pMX64 | Constitutive TS-TS expression vector (PSV40-TetR-ScbR-KRAB-pA). | This work |
| KRAB was excised from pMF205 using | ||
| pMX65 | SCB1-inducible SEAP expression vector (PSPS-SEAP-pA; PSPS, PSV40- OPapRI). | This work |
| OPapRI-SEAP was PCR-amplified from pSEAP2-Control using oligonucleotides OMX75 (5′- GTAATAAGCTTGAGGCCATTGACAAACCGACCGTGCCGTTTTTTTCCTGCAGGCCACCATGCTGCTGCTGCTGCTGC TGCTGGG-3′) and OMX24 (5′-CTTGAGCACATAGCCTGGACCGTTTCCGTA-3′), restricted with | ||
| pMX67 | TET-inducible SEAP expression vector (PtTSON2-SEAP-pA; PtTSON2, PSV40- tetO2). | This work |
| tetO2-SEAP was PCR-amplified from pSEAP2-Control using oligonucleotides OMX77 (5′- GTAATAAGCTTTCTATCAGTGATAGAGAAAAGTGAAAGTCGAGCTCTATCAGTGATAGCCTGCAGGCCACCATGCTGCTGCTGCTGCTGCTGCTGGG-3′) and OMX24 (5′-CTTGAGCACATAGCCTGGACCGTTTCCGTA-3′), restricted with | ||
| pFS1 | Constitutive TP-TA expression vector (PSV40- TetR-TtgR-pA). | This work |
| TtgR was excised from pMX31 using |
GLuc, Gaussia princeps luciferase; KRAB, Krueppel-associated box domain of the human kox-1 gene; OPapRI, SCA-specific operator; OTtgR, TtgA1-specific operator; pA, polyadenylation site; PhCMV, human cytomegalovirus immediate early promoter; PhCMV*−1, TET-responsive promoter (tetO7-PhCMVmin); PhCMVmin, minimal version of PhCMV; PSPA, SCB1-responsive promoter (OPapRI-PhCMVmin); PST-TA/TS-TA1, TET- and SCB1-responsive promoter (tetO-21bp-OPapRI-PhCMVmin); PST-TA/TS-TA2, TET- and SCB1-responsive promoter (tetO-21bp-tetO-21bp-OPapRI-PhCMVmin); PSV40, simian virus 40 promoter; PSPS, SCB1-inducible promoter (PSV40-OPapRI); PtTSON2, TET-inducible promoter (PSV40-tetO2; tetO2, tetO-21bp-tetO); PT-TA, hybrid phloretin- and TET-dependent transactivator (TtgR-TetR-VP16); PTS-TA, hybrid phloretin-, TET and SCB1-dependent transactivator (TtgR-TetR-ScbR-VP16); PTtgR1, phloretin-responsive promoter (OTtgR-PhCMVmin); P1VanO2, vanillic acid-responsive promoter (vanO2-PhCMVmin); SCA, SCB1-dependent transactivator (ScbR-VP16); ScbR, Streptomyces coelicolor quorum-sensing receptor; SCB1, S.coelicolor butanolide 1, 2-(1'-hydroxy-6-methylheptyl)-3-(hydroxymethyl)-butanolide; SEAP, human placental secreted alkaline phosphatase; ST-TA, hybrid SCB1- and tetracycline-dependent transactivator (ScbR-TetR-VP16); ST-TS, hybrid SCB1- and TET-dependent transsilencer (ScbR-TetR-KRAB); SP-TA, hybrid SCB1- and phloretin dependent transactivator (ScbR-TtgR-VP16); tetO2, tetO7, tTA-specific operator sequence; TetR, E. coli Tn10-derived repressor of the TET resistance gene; TP-TA, hybrid phloretin- and TET-dependent transactivator (TetR-TtgR-VP16); TS-TA, hybrid TET- and SCB1-dependent transactivator (TetR-ScbR-VP16); TS-TS, hybrid TET- and SCB1-dependent transsilencer (TetR-ScbR-KRAB); tTA, TET-dependent transactivator (TetR-VP16); tTS, TET-dependent transsilencer (TetR-KRAB); TtgA1, phloretin-dependent transactivator (TtgR-VP16); TtgR, repressor of the Pseudomonas putida DOT-T1E ABC multi-drug efflux pump; TV-TA, hybrid TET- and vanillic acid-dependent transactivator (TetR-VanR-VP16); VanA1, vanillic acid-dependent transactivator (VanR-VP16); VanO2, VanR-specific operator; VanR, repressor of the Caulobacter crescentus VanAB gene cluster; VP16, Herpes simplex virus-derived transactivation domain; VT-TA, hybrid vanillic acid- and TET-dependent transactivator (VanR-TetR-VP16); zeo, zeocin resistance gene.
Figure 1.Tandem TetR-family scheme. (A) Multiple alignment analysis of Mce3R’s predicted alpha helical secondary structure reveals a double TetR-family signature consisting of typical DNA-binding HTH and ligand-binding domain (LBD) domains that is present in over 200 other putative Actinomycetes repressor proteins. Therefore, Mce3R may be a prototype of a larger family of natural repressor fusion proteins sharing specific transcription-control characteristics. (B) Synthetic bipartite TetR-family repressor-derived mammalian transcription factors with dual input–output control capacity. Bipartite TetR-family repressor-derived mammalian transactivator variants assembled by fusing the TET- and γ-butyrolactone-dependent repressor proteins (TetR, ScbR) to the Herpex simplex virus-derived transactivation domain (VP16). Corresponding target promoters contain specific operator sites (tetO7, OPapR1) immediately 5′ of a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin) and control expression of the human placental SEAP gene. (C) Interaction diagram of individual and tandem transactivator components with corresponding expression units.
Figure 2.Performance of bipartite TetR-family transcription factors. (A) Regulation characteristics of the ScbR-TetR-VP16 (ST-TA) and TetR-ScbR-VP16 (TS-TA) transactivators. HEK-293T cells were co-transfected with ST-TA (pMX1) or TS-TA (pMX10) and either PhCMV*−1- (pMF111) or PSPA- (pWW124) driven SEAP expression vectors. Isogenic cultures expressing tTA (pSAM200) or SCA (pWW122) instead of ST-TA (pMX1) were used as controls. Cells were grown for 48 h in the presence or absence of the trigger molecules TET or the γ-butyrolactone (SCB1) before the SEAP levels in the culture supernatant were quantified. (B) TET- and γ-butyrolactone- (SCB1) adjustable ST-TA-driven transgene expression. HEK-293T cells were transfected with either pMX1/pWW124 or pMX1/pMF111 and cultivated for 48 h in the presence of different concentrations of TET or SCB1 before SEAP was scored in the culture supernatant. HEK-293T transfected with either tTA (pSAM200) or SCA (pWW122) instead of ST-TA (pMX1) were used as controls. (C) Synthetic bipartite TetR-family repressor-derived mammalian transsilencers. Tandem TetR-family repressor-derived mammalian transsilencer variants assembled by fusing the TET- and γ-butyrolactone-dependent repressor proteins (TetR, ScbR) to the KRAB domain of the human kox-1 gene. Corresponding target promoters contain specific operator sites (tetO2, OPapR1) immediately 3′ of the constitutive simian virus 40 promoter (PSV40) and control expression of the human placental SEAP. (D) Performance of the ScbR-TetR-KRAB (ST-TS) and TetR-ScbR-KRAB (TS-TS) transsilencers. HEK-293T cells were co-transfected with ST-TS (pMX63) or TS-TS (pMX64) and either PSPS- (pMX65) or PtTSON2- (pMX67) driven SEAP expression vectors and grown for 48 h in the presence (1 µg/ml) or absence of the trigger molecules TET or the γ-butyrolactone (SCB1) before SEAP levels were scored in the culture supernatant. Isogenic cultures transfected with either pMX65 or pMX67, but no transsilencer-encoding plasmids were used as controls.
Figure 3.Characterization of synthetic bi- and tri-partite TetR-family transactivators. (A) Bi- and tri-partite TetR-family repressor-derived mammalian transactivator variants assembled by fusing the TET-, phloretin- and γ-butyrolactone-dependent repressor proteins (TetR, TtgR, ScbR) to the Herpex simplex virus-derived transactivation domain (VP16). All multi-partite transactivator-encoding expression units are driven by the constitutive simian virus 40 promoter (PSV40) and contain a polyadenylation signal (pA). Corresponding target promoters contain specific operator sites (tetO7, OTtgR, OPapR1) immediately 5′ of a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin) and control expression of the human placental SEAP. (B) Regulation performance of the TtgR-TetR-VP16 (PT-TA) and TetR-TtgR-VP16 (TP-TA) transactivators. HEK-293T cells were co-transfected with PT-TA (pMX29) or TP-TA (pFS1) and either PhCMV*−1- (pMF111) or PTtgR1- (pMG10) driven SEAP expression vectors. Isogenic cultures expressing tTA (pSAM200) or TtgA1 (pMG11) instead of PT-TA (pMX29) or TP-TA (pFS1) were used as controls. Cells were grown for 48 h in the presence or absence of the trigger molecules TET (1 µg/ml) or phloretin (PLT, 0.2 µg/ml) before SEAP levels were scored in the culture supernatant. (C) Regulation performance of the tripartite TtgR-TetR-ScbR-VP16 transactivator (PTS-TA). HEK-293T cells were co-transfected with PTS-TA (pMX27) and either PhCMV*−1- (pMF111), PSPA- (pWW124) or PTtgR1- (pMG10) driven SEAP expression vectors. Isogenic cultures expressing tTA (pSAM200), SCA (pWW122) or TtgA1 (pMG11) instead of PTS-TA (pMX27) were used as controls. Cells were grown for 48 h in the presence or absence of the trigger molecules TET (1 µg/ml), γ-butyrolactone (SCB1, 1 µg/ml) or the phloretin (PLT, 0.2 µg/ml) before SEAP levels were profiled in the culture supernatant.
Figure 4.Bi-partite TetR/GntR-family repressor-derived mammalian transactivators with dual input–output control capacity. (A) Bi-partite TetR/GntR-family repressor-derived mammalian transactivator variants assembled by fusing the TET- and vanillic acid-responsive repressor proteins (TetR, VanR) to the Herpex simplex virus-derived transactivation domain (VP16). The bi-partite transactivator-encoding expression units are driven by the constitutive simian virus 40 promoter (PSV40) and contain a polyadenylation signal (pA). Corresponding target promoters contain domain-specific operator sites VanO2 and tetO7 immediately 5′ of a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin) that controls expression of the human placental SEAP. (B) Regulation performance of the TetR-VanR-VP16 (TV-TA) and VanR-TetR-VP16 (VT-TA) transactivators. HEK-293T cells were co-transfected with TV-TA (pMX6) or VT-TA (pMX25) and either PhCMV*−1- (pMF111) or P1VanO2- (pMG252) driven SEAP expression vectors. Isogenic cultures expressing tTA (pSAM200) or VanA1 (pMG250) instead of TV-TA (pMX6) or VT-TA (pMX25) were used as controls. Cells were grown for 48 h before SEAP levels were quantified in the culture supernatant. (C) Trigger responsiveness of the VanR-TetR-VP16 (VT-TA) transactivator. HEK-293T cells were co-transfected with VT-TA (pMX25) and either PhCMV*−1- (pMF111) or P1VanO2- (pMG252) driven SEAP expression vectors and grown for 48 h in the presence and absence of the trigger molecules vanillic acid (VAC, 17 µg/ml) or TET (1 µg/ml) before SEAP levels were scored in the culture supernatant.
Figure 5.Two-gene control dynamics of the ST-TA transactivator. (A) Independent control of two different transgenes. HEK-293T cells were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-driven SEAP- (pWW124) and PhCMV*−1-driven GLuc- (pDA43) expression vectors at a high transactivator-to-reporter ratio (20:1:1) and grown for 48 h in culture medium containing increasing concentrations of TET or γ-butyrolactone (SCB1) before SEAP and GLuc levels were quantified in the culture supernatant. (B) DPDT relay switch characteristics.
HEK-293T cells were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-driven SEAP- (pWW124) and PhCMV*−1-driven GLuc- (pDA43) expression vectors at a low transactivator-to-reporter ratio (1:12:12) and grown for 48 h in culture medium containing increasing concentrations of TET before SEAP and GLuc levels were quantified in the culture supernatant. (C) HEK-293T cells were co-transfected with the tTA- and SCA- expression vectors (pSAM200, pWW122) and corresponding reporter plasmids pDA43 (PhCMV*−1-GLuc) and pWW124 (PSPA-SEAP) (ratio 1:1:5:5), grown for 48 h in culture medium containing increasing concentrations of TET before expressed SEAP and GLuc levels were quantified in the culture supernatant. (D) DPDT relay switch characteristics of hMSC-TERT cells. hMSC-TERT cells were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-driven SEAP- (pWW124) and PhCMV*−1-driven GLuc- (pDA43) expression vectors in a low transactivator-to-reporter ratio (1:12:12) and grown for 48 h in culture medium containing increasing concentrations of TET before SEAP and GLuc levels were quantified in the culture supernatant. (E) Reversibility of ST-TA-mediated DPDT relay switch characteristics. HEK-293T cells were co-transfected with the ST-TA-encoding plasmid pMX1, the PSPA-driven SEAP- (pWW124) and PhCMV*−1-driven GLuc- (pDA43) expression vectors in a low transactivator-to-reporter ratio (1:12:12) and grown for 24 h in the presence (1 µg/ml) or absence of TET and SEAP, and GLuc levels were profiled in the culture supernatant. The same cells were then washed and incubated with fresh medium and grown for another 24 h in the presence (TET, 1 µg/ml) or absence of TET (TET to no TET), before SEAP and GLuc levels were profiled in the culture supernatant. (F) Schematic of the electric and genetic DPDT relay switch.
Figure 6.(A) ST-TA driven by a minimal version of the human cytomegalovirus immediate early promoter. (B) Western blot-based analysis of ST-TA expression levels. Lanes left to right: ST-TA (pMX1) transiently transfected into HEK-293T; HEK-293TST-TA stably expressing ST-TA at low levels; tTA (pSAM200) transiently transfected into HEK-293T; non-transfected HEK-293T cells used as control. (C) HEK-293TST-TA cells were co-transfected with the PSPA-driven SEAP (pWW124) and PhCMV*−1-driven GLuc (pDA43) expression vectors (plasmid ratio 1:1) and grown for 24 h in culture medium containing increasing concentrations of TET before SEAP levels, and GLuc were profiled in the culture supernatant. (D) Compatibility of the DPDT relay with tTA and SCA. HEK-293TST-TA cells were co-transfected with the PSPA-driven SEAP (pWW124) and PhCMV*−1-driven GLuc (pDA43) expression plasmids (ratio 13:20:20), and either the tTA (pSAM200) or SCA (pWW122) expression vectors, and grown for 48 h in the presence or absence of 1 µg/ml TET before SEAP and GLuc levels were profiled in the culture supernatant.
Figure 7.Regulation characteristics of ST-TA and TS-TA-specific hybrid promoters. (A) Schematic of ST-TA- and TS-TA-specific promoter variants combining one (PST-TA/TS-TA1) or two (PST-TA/TS-TA2) tetOs (orange) with a single ScbR-specific binding site (OPapRI, blue), all separated by two helical turns, with a minimal version of the human cytomegalovirus immediate early promoter. (B) Maximum ST-TA- and TS-TA-dependent induction of the hybrid promoters in the absence of any control molecules. HEK-293T cells were co-transfected with either the SCA- (pWW122), tTA- (pSAM200), ST-TA- (pMX1) or TS-TA- (pMX10) encoding plasmids in combination with either PST-TA/TS-TA1 (pMX8, gray) or PST-TA/TS-TA2 (pMX9, black) and cultivated for 48 h before SEAP levels were quantified in the culture supernatant. (C) TET- and γ-butyrolactone (SCB1)-regulated TS-TA (pMX10)-mediated transactivation of the pMX9-encoded hybrid promoter enables programming of discrete SEAP expression levels in response to a specific combination of inhibitory concentrations (1 µg/ml) of TET and SCB1. HEK-293T cells were co-transfected with pMX10 (TS-TA) and pMX9 (PST-TA/TS-TA2) and cultivated in medium containing different combinations of trigger compounds. HEK-293T cells exclusively transfected with pMX9 (PST-TA/TS-TA2) were used as control. Cells were grown for 48 h before SEAP levels were quantified in the culture supernatant.